Loading...
•
Mar 31, 2023
Janux Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023 and provided a business update.
Key Takeaways
Janux Therapeutics reported first quarter 2023 financial results, including cash and cash equivalents and short-term investments of $316.9 million. The company's research and development expenses were $15.9 million, and general and administrative expenses were $6.5 million, resulting in a net loss of $17.5 million.
First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors.
Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023.
Cash and cash equivalents and short-term investments totaled $316.9 million at the end of the first quarter 2023.
PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in mCRPC.
Revenue by Segment
Forward Guidance
Janux anticipates providing an interim clinical update from the PSMA-TRACTr (JANX007) trial in the second half of 2023. In addition, Janux expects to select a development candidate for its TROP2-TRACTr in 2023.
Positive Outlook
- PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in mCRPC.
- First patient dosed with EGFR-TRACTr program (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors.
- PD-L1xCD28 TRACIr (JANX009) on-track for an IND submission in 2023.
- TROP2-TRACTr evaluations to support development candidate selection are ongoing.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...